Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry
研究概览
简要总结
The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors.
A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
- •For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
- •For the control group: patient who had a normal pregnancy
排除标准
- •Patient who gave birth naturally
- •Underage patients or under guardianship
- •Patients who do not speak or read French
- •Childbirth under X
结局指标
主要结局
Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry
时间窗: At delivery
Measured by placenta pathological examination (immunohistochemistry technical).
Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry
时间窗: At delivery
Measured by placenta pathological examination (immunohistochemistry technical).
次要结局
- Presence of at least one chronic maternal pathologies describe below(At delivery)
- Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry(At delivery)
- Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).(At delivery)
- Presence of an anticoagulant treatment(At delivery)
- Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry(At delivery)
- Obstetric history(At delivery)
- Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry(At delivery)